Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Quantum Biopharma ( (TSE:QNTM) ).
Quantum BioPharma announced on May 16, 2025, its participation in the Sidoti Micro-Cap Investor Conference and the A.G.P. Virtual Healthcare Conference, scheduled for May 21 and May 22, 2025, respectively. The company’s Head of Finance and M&A, Jason Sawyer, will engage with institutional investors through presentations and one-on-one meetings, potentially enhancing Quantum BioPharma’s industry visibility and investor relations.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is advancing its lead compound, Lucid-MS, which targets multiple sclerosis, and maintains a strategic investment portfolio through its subsidiary, FSD Strategic Investments Inc.
Average Trading Volume: 8,761
Technical Sentiment Signal: Sell
Current Market Cap: C$25.73M
Find detailed analytics on QNTM stock on TipRanks’ Stock Analysis page.